

Patrizio Giacomini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/530736/publications.pdf>

Version: 2024-02-01

116
papers

3,502
citations

147726

31
h-index

168321

53
g-index

118
all docs

118
docs citations

118
times ranked

4434
citing authors

#	ARTICLE	IF	CITATIONS
1	Antagomir-17-5p Abolishes the Growth of Therapy-Resistant Neuroblastoma through p21 and BIM. PLoS ONE, 2008, 3, e2236.	1.1	345
2	Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 6719-6723.	3.3	124
3	Antibody-drug conjugates: targeting melanoma with cisplatin encapsulated in protein-cage nanoparticles based on human ferritin. Nanoscale, 2013, 5, 12278.	2.8	119
4	Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions. Journal of Immunology, 1983, 130, 1462-6.	0.4	108
5	Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells. Cancer Research, 1983, 43, 660-8.	0.4	105
6	Modulation by recombinant DNA leukocyte (alpha) and fibroblast (beta) interferons of the expression and shedding of HLA- and tumor-associated antigens by human melanoma cells. Journal of Immunology, 1984, 133, 1649-55.	0.4	97
7	Expression of Endoplasmic Reticulum Aminopeptidases in EBV-B Cell Lines from Healthy Donors and in Leukemia/Lymphoma, Carcinoma, and Melanoma Cell Lines. Journal of Immunology, 2006, 176, 4869-4879.	0.4	88
8	Improved Doxorubicin Encapsulation and Pharmacokinetics of Ferritin-Fusion Protein Nanocarriers Bearing Proline, Serine, and Alanine Elements. Biomacromolecules, 2016, 17, 514-522.	2.6	88
9	Altered expression of endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 in transformed non-lymphoid human tissues. Journal of Cellular Physiology, 2008, 216, 742-749.	2.0	85
10	Expression of tumor antigen correlated with metastatic potential of Lewis lung carcinoma and B16 melanoma clones in mice. Cancer Research, 1986, 46, 5772-8.	0.4	77
11	Human Leukocyte Antigen E Contributes to Protect Tumor Cells from Lysis by Natural Killer Cells. Neoplasia, 2011, 13, 822-IN14.	2.3	73
12	IRF1 and NF-kB Restore MHC Class I-Restricted Tumor Antigen Processing and Presentation to Cytotoxic T Cells in Aggressive Neuroblastoma. PLoS ONE, 2012, 7, e46928.	1.1	69
13	NF- κ B, and not MYCN, Regulates MHC Class I and Endoplasmic Reticulum Aminopeptidases in Human Neuroblastoma Cells. Cancer Research, 2010, 70, 916-924.	0.4	65
14	Natural Killer Cells Efficiently Reject Lymphoma Silenced for the Endoplasmic Reticulum Aminopeptidase Associated with Antigen Processing. Cancer Research, 2011, 71, 1597-1606.	0.4	64
15	Distinctive Features of the α 1-Domain a Helix of HLA-C Heavy Chains Free of β 2-Microglobulin. Human Immunology, 1996, 46, 69-81.	1.2	61
16	Selective delivery of doxorubicin by novel stimuli-sensitive nano-ferritins overcomes tumor refractoriness. Journal of Controlled Release, 2016, 239, 10-18.	4.8	60
17	Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations. Journal of Experimental and Clinical Cancer Research, 2018, 37, 47.	3.5	60
18	High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis. Journal of Translational Medicine, 2011, 9, 184.	1.8	55

#	ARTICLE	IF	CITATIONS
19	Melanomas and melanoma cell lines do not express HLA-G, and the expression cannot be induced by $\hat{\text{I}}^3\text{IFN}$ treatment. <i>Tissue Antigens</i> , 2000, 56, 30-37.	1.0	47
20	Regulation of class II MHC gene expression by interferons: insights into the mechanism of action of interferon (review). <i>Anticancer Research</i> , 1988, 8, 1153-61.	0.5	47
21	Detection of soluble ERBB2 in breast cancer cell lysates using a combined label-free/fluorescence platform based on Bloch surface waves. <i>Biosensors and Bioelectronics</i> , 2017, 92, 125-130.	5.3	41
22	Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review). <i>International Journal of Oncology</i> , 2018, 53, 1395-1434.	1.4	41
23	Production and Characterization of the Murine Monoclonal Antibody 2G10 to a Human T4-Tyrosinase Epitope. <i>Journal of Investigative Dermatology</i> , 1991, 96, 446-451.	0.3	40
24	HLA-E: Strong Association with $\hat{\text{I}}^2$ -Microglobulin and Surface Expression in the Absence of HLA Class I Signal Sequence-Derived Peptides. <i>Journal of Immunology</i> , 2008, 181, 5442-5450.	0.4	37
25	Programmable Interactions of Functionalized Single Bioparticles in a Dielectrophoresis-Based Microarray Chip. <i>Analytical Chemistry</i> , 2013, 85, 8219-8224.	3.2	37
26	HLA heavy chains free of $\hat{\text{I}}^2$ -microglobulin: distribution in normal tissues and neoplastic lesions of non-lymphoid origin and interferon $\hat{\text{I}}^3$ responsiveness. <i>Tissue Antigens</i> , 1997, 50, 555-566.	1.0	36
27	Expression of single-chain antibodies in transgenic plants. <i>Vaccine</i> , 2005, 23, 1823-1827.	1.7	36
28	A Single Bottleneck in HLA-C Assembly. <i>Journal of Biological Chemistry</i> , 2008, 283, 1267-1274.	1.6	36
29	Major Histocompatibility Complex Class I and Tumour Immuno-Evasion: How to Fool T Cells and Natural Killer Cells at One Time. <i>Current Oncology</i> , 2012, 19, 39-41.	0.9	34
30	Recombinant human IFN-gamma, but not IFN-alpha or IFN-beta, enhances MHC- and non-MHC-encoded glycoproteins by a protein synthesis-dependent mechanism. <i>Journal of Immunology</i> , 1988, 140, 3073-81.	0.4	32
31	Antigenic heterogeneity of skin tumors of nonmelanocyte origin: analysis with monoclonal antibodies to tumor-associated antigens and to histocompatibility antigens. <i>Journal of the National Cancer Institute</i> , 1983, 71, 439-47.	3.0	32
32	Production and Characterization of Murine mAbs to the Extracellular Domain of Human Neu Oncogene Product GP185HER2. <i>Hybridoma</i> , 1992, 11, 519-527.	0.9	31
33	Analysis of the interaction between a human high molecular weight melanoma-associated antigen and the monoclonal antibodies to three distinct antigenic determinants. <i>Journal of Immunology</i> , 1985, 135, 696-702.	0.4	30
34	The antigen processing machinery of class I human leukocyte antigens: linked patterns of gene expression in neoplastic cells. <i>Cancer Research</i> , 2003, 63, 4119-27.	0.4	30
35	Modulation of tumor associated antigen expression and shedding by recombinant human leukocyte and fibroblast interferons. , 1985, 31, 209-236.		29
36	Melanoma molecular classes and prognosis in the postgenomic era. <i>Lancet Oncology</i> , The, 2012, 13, e205-e211.	5.1	29

#	ARTICLE	IF	CITATIONS
37	T and NK cells: two sides of tumor immunoevasion. <i>Journal of Translational Medicine</i> , 2013, 11, 30.	1.8	29
38	The impact of monoclonal antibodies on the study of human malignant melanoma. <i>Journal of Cutaneous Pathology</i> , 1983, 10, 514-528.	0.7	28
39	Functional expression of a single-chain antibody to ErbB-2 in plants and cell-free systems. <i>Journal of Translational Medicine</i> , 2006, 4, 39.	1.8	28
40	A Distinctive microRNA (miRNA) Signature in the Blood of Colorectal Cancer (CRC) Patients at Surgery. <i>Cancers</i> , 2020, 12, 2410.	1.7	27
41	Precision diagnostics of Ewing's sarcoma by liquid biopsy: circulating <i>EWS-FLI1</i> fusion transcripts. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877433.	1.4	26
42	Liquid biopsy in mice bearing colorectal carcinoma xenografts: gateways regulating the levels of circulating tumor DNA (ctDNA) and miRNA (ctmiRNA). <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 124.	3.5	25
43	Modulation of the antigenic phenotype of early-passage human melanoma cells derived from multiple autologous metastases by recombinant human leukocyte, fibroblast and immune interferon. <i>International Journal of Cancer</i> , 1990, 46, 539-545.	2.3	24
44	Potential of growth suppression and modulation of the antigenic phenotype in human melanoma cells by the combination of recombinant human fibroblast and immune interferons. <i>Cancer Immunology, Immunotherapy</i> , 1991, 32, 382-390.	2.0	24
45	A melanoma immune response signature including Human Leukocyte Antigen. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 103-112.	1.5	24
46	Direct plasmonic detection of circulating RAS mutated DNA in colorectal cancer patients. <i>Biosensors and Bioelectronics</i> , 2020, 170, 112648.	5.3	24
47	Unknown primary tumors. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2011, 1816, 13-24.	3.3	23
48	Distamycin inhibits the binding of a nuclear factor to the -278/-256 upstream sequence of the human HLA-DR1 gene. <i>Biochemical Pharmacology</i> , 1991, 41, 497-502.	2.0	22
49	Binding of Epstein-Barr virus nuclear antigen 1 to DNA: inhibition by distamycin and two novel distamycin analogues. <i>European Journal of Pharmacology</i> , 1994, 267, 143-149.	2.7	22
50	Conformation and surface expression of free HLA-CW1 heavy chains in the absence of β 2-microglobulin. <i>Human Immunology</i> , 1997, 53, 23-33.	1.2	22
51	cDNA-array profiling of melanomas and paired melanocyte cultures. <i>Journal of Cellular Physiology</i> , 2006, 207, 697-705.	2.0	22
52	HLA-A, -B, -C Expression in Colon Carcinoma Mimics That of the Normal Colonic Mucosa and is Prognostically Relevant. <i>American Journal of Surgical Pathology</i> , 2007, 31, 76-84.	2.1	22
53	Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3837.	1.8	22
54	Antigenic profile of human melanoma cells. Analysis with monoclonal antibodies to histocompatibility antigens and to melanoma-associated antigens. <i>Journal of Cutaneous Pathology</i> , 1983, 10, 225-237.	0.7	21

#	ARTICLE	IF	CITATIONS
55	Heterogeneous distribution of actin, myosin, fibronectin and basement membrane antigens in primary and metastatic human breast cancer. <i>Virchows Archiv A, Pathological Anatomy and Histopathology</i> , 1984, 405, 69-83.	1.4	21
56	Lack of correlation between hypomethylation and expression of the HLA-DR β gene. <i>European Journal of Immunology</i> , 1986, 16, 365-369.	1.6	20
57	Class I HLA Folding and Antigen Presentation in β 2-Microglobulin-Defective Daudi Cells. <i>Journal of Immunology</i> , 2009, 182, 3609-3617.	0.4	20
58	Multiple epitope recognition: An approach to improved radioimmunodetection of tumor-associated antigens. <i>International Journal of Cancer</i> , 1987, 39, 729-736.	2.3	19
59	Detection of Tumor DNA in Human Plasma with a Functional PLL-Based Surface Layer and Plasmonic Biosensing. <i>ACS Sensors</i> , 2021, 6, 2307-2319.	4.0	19
60	Cross-sectional analysis of circulating tumor DNA in primary colorectal cancer at surgery and during post-surgery follow-up by liquid biopsy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 69.	3.5	18
61	Biosynthesis of HLA-C heavy chains in melanoma cells with multiple defects in the expression of HLA-A, -B, -C molecules. <i>British Journal of Cancer</i> , 1999, 80, 639-649.	2.9	17
62	Functional expression of a single-chain antibody specific for the HER2 human oncogene in a bacterial reducing environment. <i>Protein Expression and Purification</i> , 2005, 44, 10-15.	0.6	17
63	Lysis-on-Chip of Single Target Cells following Forced Interaction with CTLs or NK Cells on a Dielectrophoresis-Based Array. <i>Journal of Immunology</i> , 2013, 191, 3545-3552.	0.4	17
64	Analysis of the NIH Workshop Monoclonal Antibodies to Human Melanoma Antigens. <i>Hybridoma</i> , 1982, 1, 473-482.	0.9	16
65	A third polypeptide associated with heavy and light chain subunits of class I HLA antigens in immune interferon-treated human melanoma cells. <i>European Journal of Immunology</i> , 1985, 15, 946-951.	1.6	16
66	mAb KUL/05 IDENTIFIES A DENATURATION-RESISTANT DETERMINANT SHARED BY CLASS II MHC PRODUCTS DR, DQ AND DP. <i>International Journal of Immunogenetics</i> , 1989, 16, 203-216.	1.2	16
67	Gene variants associated to malignant thyroid disease in familial adenomatous polyposis: A novel APC germline mutation. <i>Journal of Endocrinological Investigation</i> , 2010, 33, 603-606.	1.8	16
68	Effect of recombinant human fibroblast interferon and mezerein on growth, differentiation, immune interferon binding and tumor associated antigen expression in human melanoma cells. <i>Anticancer Research</i> , 1986, 6, 765-74.	0.5	16
69	Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNF α -based isolated limb perfusion. <i>In Vivo</i> , 2009, 23, 347-52.	0.6	16
70	Up-regulation of activating and inhibitory NKG2 receptors in allogeneic and autologous hematopoietic stem cell grafts. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 98.	3.5	15
71	Ontogeny of murine I-Ak antigens in tissue of nonlymphoid origin. <i>Immunogenetics</i> , 1981, 14, 359-365.	1.2	14
72	Some evidence for the in vivo functional activation of suppressor T cells in asymptomatic patients with hemophilia A receiving factor VIII concentrates. <i>Clinical Immunology and Immunopathology</i> , 1985, 34, 27-38.	2.1	14

#	ARTICLE	IF	CITATIONS
73	Regulation of the Expression of Class II Genes of the Human Major Histocompatibility Complex in Tumor Cells. <i>Annals of the New York Academy of Sciences</i> , 1987, 511, 292-307.	1.8	14
74	Human HLA-DR β gene: a rare oligonucleotide (GTATA) identifies an upstream sequence required for nuclear protein binding. <i>FEBS Letters</i> , 1990, 268, 51-54.	1.3	14
75	Membrane expression of HLA-Cw4 free chains in activated T cells of transgenic mice. <i>Immunogenetics</i> , 1995, 42, 368-75.	1.2	13
76	High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 63.	3.5	13
77	Impaired Assembly Results in the Accumulation of Multiple HLA-C Heavy Chain Folding Intermediates. <i>Journal of Immunology</i> , 2005, 175, 6651-6658.	0.4	11
78	Monoclonal antibodies to HLA β bind epitopes carried by unfolded β 2-microglobulin free heavy chains. <i>European Journal of Immunology</i> , 2015, 45, 2356-2364.	1.6	11
79	Sub-apoptotic dosages of pro-oxidant vitamin cocktails sensitize human melanoma cells to NK cell lysis. <i>Oncotarget</i> , 2015, 6, 31039-31049.	0.8	11
80	Differential Susceptibility to Modulation by Recombinant Immune Interferon of HLA-DR and -DQ Antigens Synthesized by Melanoma COLO 38 Cells. <i>Hybridoma</i> , 1986, 5, 277-288.	0.9	10
81	Bloch Surface Waves Biosensors for High Sensitivity Detection of Soluble ERBB2 in a Complex Biological Environment. <i>Biosensors</i> , 2017, 7, 33.	2.3	10
82	Lymphoid stroma of Warthin's tumor: Phenotypic analogies with gut-associated lymphoid tissue. <i>Clinical Immunology and Immunopathology</i> , 1985, 34, 39-47.	2.1	9
83	Tissue-specific expression of the HLA-DRA gene in transgenic mice. <i>Immunogenetics</i> , 1991, 34, 385-391.	1.2	9
84	Distamycin analogues with improved sequence-specific DNA binding activities. <i>Biochemical Pharmacology</i> , 1994, 48, 1583-1591.	2.0	9
85	Sequencing of an upstream region of the human HLA-DRA gene containing X' and Y' boxes. <i>Nucleic Acids Research</i> , 1995, 23, 1671-1678.	6.5	9
86	An ID card for tumour cell lines: HLA typing can help. <i>Lancet Oncology</i> , The, 2001, 2, 658.	5.1	9
87	Bioassay engineering: a combined label-free and fluorescence approach to optimize HER2 detection in complex biological media. <i>Analytical and Bioanalytical Chemistry</i> , 2020, 412, 3509-3517.	1.9	9
88	Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer. <i>Molecular Cancer</i> , 2021, 20, 151.	7.9	9
89	METHYLATION PATTERN OF THE HLA-DR β GENE IN HUMAN TISSUES. <i>International Journal of Immunogenetics</i> , 1990, 17, 51-66.	1.2	7
90	First-trimester human trophoblast is class II major histocompatibility complex mRNA+/antigen β 2-microglobulin β . <i>Human Immunology</i> , 1994, 39, 281-289.	1.2	7

#	ARTICLE	IF	CITATIONS
91	DRÎ±:EÎ² heterodimers in DRA transgenic mice hinder expression of EÎ±:EÎ² molecules and are more efficient in antigen presentation. <i>International Immunology</i> , 1995, 7, 1927-1938.	1.8	7
92	N-Linked Glycosylation Selectively Regulates the Generic Folding of HLA-Cw1. <i>Journal of Biological Chemistry</i> , 2008, 283, 16469-16476.	1.6	7
93	Human melanoma-associated antigens identified with monoclonal antibodies. <i>Research in Clinic and Laboratory</i> , 1982, 12, 517-38.	0.3	7
94	Transgenic mice mimic the methylation pattern of the human HLA-DRÎ± gene. <i>Biochemical and Biophysical Research Communications</i> , 1991, 175, 459-466.	1.0	6
95	Membrane Compartmentalization of Melanosomal gp75. <i>Journal of Investigative Dermatology</i> , 1992, 98, 340-342.	0.3	6
96	Characterization of a Major Histocompatibility Complex Class II X-Box-Binding Protein Enhancing Tat-Induced Transcription Directed by the Human Immunodeficiency Virus Type 1 Long Terminal Repeat. <i>Journal of Virology</i> , 2000, 74, 8989-9001.	1.5	6
97	HLA-E and the origin of immunogenic self HLA epitopes. <i>Molecular Immunology</i> , 2010, 47, 1661-1662.	1.0	6
98	Comment on "Influence of HLA-C Expression Level on HIV Control". <i>Science</i> , 2013, 341, 1175-1175.	6.0	5
99	Molecular heterogeneity and shedding of a high-molecular-mass melanoma-associated antigen identified with monoclonal antibodies. <i>Clinical Chemistry</i> , 1982, 28, 2347-50.	1.5	5
100	Modular usage of the HLA-DRA promoter in extra-hematopoietic and hematopoietic cell types of transgenic mice. <i>FEBS Journal</i> , 2005, 272, 3214-3226.	2.2	4
101	Isolation of viable melanoma cells from surgically removed lesions using dishes coated with monoclonal antibody to a high molecular weight melanoma associated antigen. <i>Journal of Immunological Methods</i> , 1983, 62, 337-346.	0.6	3
102	Analysis of the human HLA-DRA gene upstream region: Evidence for a stem-loop array directed by nuclear factors. <i>Biochimie</i> , 1999, 81, 219-228.	1.3	3
103	HLA-A, -B, -C Genotyping and Expression in Human Nonlymphoid Tumor Cell Lines. <i>Journal of Immunotherapy</i> , 1999, 22, 7-15.	1.2	3
104	CG Dinucleotides of class II MHC genes are mutation hot-spots. <i>Cytotechnology</i> , 1988, 1, 133-138.	0.7	2
105	Methylation state of the human HLA-DRA gene in T-lymphocytes and B-lymphocytes of transgenic mice. Lack of methylation at one 5'-GCCG site is not required for gene expression. <i>FEBS Journal</i> , 1993, 218, 485-492.	0.2	2
106	Methylation State of Cellular Genes and Oncogenes as a Marker of Malignancy in Human Carcinomas. <i>Tumori</i> , 1989, 75, 321-328.	0.6	1
107	Antigenic modulation of metastatic breast and ovary carcinoma cells by intracavitary injection of IFN-Î±. <i>British Journal of Cancer</i> , 1992, 66, 342-344.	2.9	1
108	Combined label-free/fluorescence platform based on Bloch surface waves biochips for cancer biomarker detection. , 2018, , .		1

#	ARTICLE	IF	CITATIONS
109	Metastatic capacity of some murine tumors and TSP-180 expression*. Cell Biology International Reports, 1986, 10, 194-194.	0.7	0
110	Quantitation of mRNA and protein products of the Ha-ras-1 proto-oncogene. Breast Cancer Research and Treatment, 1990, 16, 287-289.	1.1	0
111	Methylation state of the human HLA-DRA gene in transgenic mice. Cytotechnology, 1991, 5, 55-56.	0.7	0
112	Identification of a novel DNase I hypersensitive site within the far upstream region of the human HLA-DRA gene. International Journal of Molecular Medicine, 2003, 12, 929.	1.8	0
113	Molecular Immunoavoidance Strategies Targeting Antigen Processing and Presentation. , 2016, , 279-296.		0
114	Photobleaching at the Surface of 1D-photonic Crystal Biochips. , 2019, , .		0
115	Label-free and fluorescence photonic crystal biochips for early cancer biomarker detection. , 2019, , .		0
116	Optical multiplexed bioassays on photonic crystals for breast cancer biomarker detection. EPJ Web of Conferences, 2021, 255, 13003.	0.1	0